.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Merck
Julphar
Farmers Insurance
Moodys
Healthtrust
Argus Health
US Department of Justice
Chubb

Generated: February 22, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Japan Patent: 2004-174770

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialYY
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-002May 29, 2013DISCNYesNo➤ Try a Free Trial➤ Try a Free TrialYY
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-003May 29, 2013RXYesYes➤ Try a Free Trial➤ Try a Free TrialYY
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialTAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialTAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-002May 29, 2013RXYesYes➤ Try a Free Trial➤ Try a Free TrialTAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
Novartis Pharms CorpTAFINLARdabrafenib mesylateCAPSULE;ORAL202806-002May 29, 2013RXYesYes➤ Try a Free Trial➤ Try a Free TrialTAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialMEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialIN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
Novartis Pharms CorpMEKINISTtrametinib dimethyl sulfoxideTABLET;ORAL204114-001May 29, 2013RXYesNo➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist